BACKGROUND
Real-world data on efficacy and safety of tarlatamab in small cell lung cancer (SCLC) remains limited.
METHODS
This retrospective study analyzed 265 tarlatamab-treated patients across 11 U.S. centers in the ONWARD-SCLC consortium (11/2023-4/2025), evaluating clinical outcomes, CRS, ICANS, and impact of pro...
Utsav Joshi, Bing-Nan Zhang, Z. Thompson et al.· Journal of Thoracic Oncology· 0 citations
CUP melanomas in self-ID POC had lower median TMB and were more likely to be pan-wildtype, reflecting differences in pathogenesis, and larger scale studies are needed to validate these findings.
J. Ross, V. Weir, Leore Lavin et al.· Journal of American Academy...· 0 citations
T-DM1 demonstrated heterogenous efficacy among HER2-amplified tumor types, with promising response and outcomes among patients with salivary gland cancer.
J. Ross, W. Wong, Lauren Schoech et al.· Clinical Cancer Research· 0 citations
Current standards of care, recent advances, and emerging approaches showing early promise for better management of SCLC are summarized and highlighted.
J. Ross, K. Hockemeyer, E. Redin et al.· The Lancet· 2 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.